BioSpace News Archive

89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that the Company’s Management will participate in a fireside chat and one-on-one investor meetings at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 12:00 PM ET.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 10:40 a.m. ET.

Curio Bioscience today announced it has commenced commercial operations with the launch of Curio Seeker, the world’s first high-resolution, whole-transcriptome spatial mapping kit.

Santhera Pharmaceuticals announces that it has secured a finalreimbursement agreement with the French authorities related to Raxone®for the treatment of Leber’s hereditary optic neuropathy and sales are expected to resume shortly.

Spexis AG announced that the Company has executed term sheets describing a clinical trial partnership with SPRIM Global Investments, a leading health sciences venture capital firm with deep industry expertise and decades of operating experience across 17 countries.

Gerresheimer AG announced a joint venture with Corning Incorporated, a leading innovator in materials science and manufacturing, to increase global access to the Velocity® Vial technology platform, addressing the need for a high-quality and cost-effective injectable drug filling process.

LEO Pharma Inc. today announced the Health Canada approval of Adtralza® (tralokinumab) for adolescent patients aged 12 to 17 with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Brendan Swift will join ATF Medical , a national provider of complex rehab technology and accessibility solutions in workers’ compensation, as vice president, payer partnerships and marketing on February 13.

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”) and Pantherna Therapeutics GmbH (“Pantherna”) today announced preclinical proof of concept for the combination of the two companies’ key technologies.

Design Therapeutics, Inc. today announced that João Siffert, M.D., president and chief executive officer, will participate in a fireside chat during the SVB Securities Virtual Global Biopharma Conference on Wednesday, February 15, 2023, at 5:00 p.m. ET.